The insulin-like growth factors (IGFs), IGF-I and IGF-II, are essential for regulating cell growth, differentiation and metastasis of a broad range of malignancies. The IGF-I/II actions are mediated through the IGF receptor type 1 (IGF-1R) and the insulin receptor (IR), which are overexpressed in multiple types of tumors. Here, we have firstly identified a human engineered antibody domain (eAd) from a phage-displayed VH library. The eAd suppressed the signal transduction of IGF-1R mediated by exogenous IGF-I or IGF-II in breast cancer cell lines through neutralizing both IGF-I and IGF-II. It also significantly inhibited the growth of breast cancer cells. Therefore, the anti-IGF-I/II eAd offers an alternative approach to target both the IGF-1R signaling pathways through the inhibition of IGF-I/II.
|Number of pages||8|
|Journal||International Journal of Biological Sciences|
|State||Published - May 21 2018|
Bibliographical noteFunding Information:
This work was supported by the Science and Technology Development Fund of Macau (FDCT/ 131/2016/A3), the Guangdong Science and Technology Program (2016A050502034 and 2017B030301018), the Guangzhou Science and Technology Program (201807010004), Natural Science Foundation of Guangdong (2015A0 30313741), Shenzhen Science and Technology Innovation Committee (JCYJ20160531171744232, JCY J20150401145529036, JCYJ20160608140912962, ZDSYS 20140509142721429), Start-up Research Grand (SRG2 016-00082-FHS) and the intramural research program of Faculty of Health Sciences, University of Macau, and National Natural Science Foundation of China (31440041, 31670753, 31770996).
© Ivyspring International Publisher.
- Affinity maturation
- Insulin-like growth factor
- Yeast display
ASJC Scopus subject areas
- Ecology, Evolution, Behavior and Systematics
- Applied Microbiology and Biotechnology
- Molecular Biology
- Developmental Biology
- Cell Biology